Back to articles

Costs of anticancer drugs have risen substantially, while clinical benefits remain similar


An observational analysis assessing trends in costs of anticancer drugs over a 10-year period compared with clinical benefits in the Journal of Oncology Practice found that monthly prices of these medications increased by a mean of 9% annually, and incremental drug costs increased by 21% annually. The magnitude of clinical benefits of these agents did not experience a similar proportional positive change.


Saluja R, et al. Examining trends in cost and clinical benefit of novel anticancer drugs over time. J Oncol Pract. 2018;14(5):e280–94.